skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: idioma: Russo remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

LYNCH, Thomas J ; BONDARENKO, Igor ; RECK, Martin ; LUFT, Alexander ; SERWATOWSKI, Piotr ; BARLESI, Fabrice ; CHACKO, Raju ; SEBASTIAN, Martin ; NEAL, Joel ; HAOLAN LU ; CUILLEROT, Jean-Marie

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2046-2054 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

SPIGEL, David R ; ERVIN, Thomas J ; GOVINDAN, Ramaswamy ; PATEL, Taral ; ORLOV, Sergey V ; WERTHEIM, Michael S ; WEI YU ; JIPING ZHA ; YAUCH, Robert L ; PATEL, Premal H ; PHAN, See-Chun ; PETERSON, Amy C ; RAMLAU, Rodryg A ; DANIEL, Davey B ; GOLDSCHMIDT, Jerome H ; BLUMENSCHEIN, George R ; KRZAKOWSKI, Maciej J ; ROBINET, Gilles ; GODBERT, Benoit ; BARLESI, Fabrice

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
3
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

ROBERT, Nicholas J ; DIERAS, Véronique ; PHAN, See-Chun ; O'SHAUGHNESSY, Joyce ; GLASPY, John ; BRUFSKY, Adam M ; BONDARENKO, Igor ; LIPATOV, Oleg N ; PEREZ, Edith A ; YARDLEY, Denise A ; CHAN, Stephen Y. T ; XIAN ZHOU

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1252-1260 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
4
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Gianni, Luca, Dr ; Eiermann, Wolfgang, MD ; Semiglazov, Vladimir, MD ; Manikhas, Alexey, MD ; Lluch, Ana, MD ; Tjulandin, Sergey, MD ; Zambetti, Milvia, MD ; Vazquez, Federico, MD ; Byakhow, Mikhail, MD ; Lichinitser, Mikhail, MD ; Climent, Miguel Angel, MD ; Ciruelos, Eva, MD ; Ojeda, Belén, MD ; Mansutti, Mauro, MD ; Bozhok, Alla, MD ; Baronio, Roberta, MSci ; Feyereislova, Andrea, MD ; Barton, Claire, MD ; Valagussa, Pinuccia ; Baselga, Jose, MD

The Lancet (British edition), 2010-01, Vol.375 (9712), p.377-384 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations
Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations

Hansen, Tine W ; Thijs, Lutgarde ; Li, Yan ; Boggia, José ; Kikuya, Masahiro ; Björklund-Bodegård, Kristina ; Richart, Tom ; Ohkubo, Takayoshi ; Jeppesen, Jørgen ; Torp-Pedersen, Christian ; Dolan, Eamon ; Kuznetsova, Tatiana ; Stolarz-Skrzypek, Katarzyna ; Tikhonoff, Valérie ; Malyutina, Sofia ; Casiglia, Edoardo ; Nikitin, Yuri ; Lind, Lars ; Sandoya, Edgardo ; Kawecka-Jaszcz, Kalina ; Imai, Yutaka ; Wang, Jiguang ; Ibsen, Hans ; OʼBrien, Eoin ; Staessen, Jan A

Hypertension (Dallas, Tex. 1979), 2010-04, Vol.55 (4), p.1049-1057 [Periódico revisado por pares]

Hagerstown, MD: American Heart Association, Inc

Texto completo disponível

Citações Citado por
6
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

SCAGLIOTTI, Giorgio V ; KRZAKOWSKI, Maciej ; PAPAI, Zsolt S ; KARASEVA, Nina ; THONGPRASERT, Sumitra ; DALMAU PORTULAS, Elsa ; PAWEL, Joachim Von ; KE ZHANG ; SELARU, Paulina ; TYE, Lesley ; CHAO, Richard C ; GOVINDAN, Ramaswamy ; SZCZESNA, Aleksandra ; STRAUSZ, Janos ; MAKHSON, Anatoly ; RECK, Martin ; WIERZBICKI, Rafal F ; ALBERT, Istvan ; THOMAS, Michael ; ABRAO MIZIARA, Jose Elias

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2070-2078 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
7
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

San Miguel, Jesús F ; Schlag, Rudolf ; Khuageva, Nuriet K ; Dimopoulos, Meletios A ; Shpilberg, Ofer ; Kropff, Martin ; Spicka, Ivan ; Petrucci, Maria Teresa ; Palumbo, Antonio ; Samoilova, Olga S ; Dmoszynska, Anna ; Abdulkadyrov, Kudrat M ; Delforge, Michel ; Jiang, Bin ; Mateos, Maria-Victoria ; Anderson, Kenneth C ; Esseltine, Dixie-Lee ; Liu, Kevin ; Deraedt, William ; Cakana, Andrew ; van de Velde, Helgi ; Richardson, Paul G

Journal of clinical oncology, 2013-02, Vol.31 (4), p.448-455 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
8
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Mega, JL, MD ; Braunwald, E, Prof ; Mohanavelu, S, MS ; Burton, P, MD ; Poulter, R, MB ; Misselwitz, F, MD ; Hricak, V, Prof ; Barnathan, ES, MD ; Bordes, P, MD ; Witkowski, A, Prof ; Markov, V, Prof ; Oppenheimer, L, PhD ; Gibson, CM, MD

The Lancet (British edition), 2009-07, Vol.374 (9683), p.29-38 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

KAUFMAN, Bella ; MACKEY, John R ; REVIL, Cédric ; JONES, Alison ; CLEMENS, Michael R ; BAPSY, Poonamalle P ; VAID, Ashok ; WARDLEY, Andrew ; TJULANDIN, Sergei ; JAHN, Michaela ; LEHLE, Michaela ; FEYEREISLOVA, Andrea

Journal of clinical oncology, 2009-11, Vol.27 (33), p.5529-5537 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
10
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations

FAN, Hong-Qi ; YAN LI ; TORP-PEDERSEN, Christian ; DOLAN, Eamon ; KUZNETSOVA, Tatiana ; STOLARZ-SKRZYPEK, Katarzyna ; TIKHONOFF, Valérie ; MALYUTINA, Sofia ; CASIGLIA, Edoardo ; NIKITIN, Yuri ; LIND, Lars ; SANDOYA, Edgardo ; THIJS, Lutgarde ; KAWECKA-JASZCZ, Kalina ; IMAI, Yutaka ; IBSEN, Hans ; O'BRIEN, Eoin ; JIGUANG WANG ; STAESSEN, Jan A ; HANSEN, Tine W ; BOGGIA, José ; KIKUYA, Masahiro ; BJÖRKLUND-BODEGARD, Kristina ; RICHART, Tom ; OHKUBO, Takayoshi ; JEPPESEN, Jorgen

Journal of hypertension, 2010-10, Vol.28 (10), p.2036-2045 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (37)
  2. Revistas revisadas por pares (74)

Data de Publicação 

De até
Refinar
  1. Antes de2002  (8)
  2. 2002Até2005  (11)
  3. 2006Até2009  (15)
  4. 2010Até2014  (37)
  5. Após 2014  (6)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (33)
  2. Japonês  (6)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.